These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32012456)

  • 1. Assessment of Serological Early Biomarker Candidates for Lung Adenocarcinoma by using Multiple Reaction Monitoring-Mass Spectrometry.
    Wu HY; Pan YY; Kopylov AT; Zgoda V; Ma MC; Wang CH; Su WC; Lai WW; Cheng PN; Liao PC
    Proteomics Clin Appl; 2020 Jul; 14(4):e1900095. PubMed ID: 32012456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualification and Verification of Serological Biomarker Candidates for Lung Adenocarcinoma by Targeted Mass Spectrometry.
    Wu HY; Goan YG; Chang YH; Yang YF; Chang HJ; Cheng PN; Wu CC; Zgoda VG; Chen YJ; Liao PC
    J Proteome Res; 2015 Aug; 14(8):3039-50. PubMed ID: 26120931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of differentially expressed plasma proteins in patients with lung adenocarcinoma using iTRAQ-coupled 2D LC-MS/MS.
    Li W; Zheng H; Qin H; Liu G; Ke L; Li Y; Li N; Zhong X
    Clin Respir J; 2018 Jun; 12(6):2036-2045. PubMed ID: 29363881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer.
    Park J; Yang JS; Jung G; Woo HI; Park HD; Kim JW; Huh W; Ko JW; Kim H; Cho JY; Lee SY
    J Proteomics; 2013 Dec; 94():302-10. PubMed ID: 24120528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential proteomic approach for identification and verification of aberrantly glycosylated proteins in adenocarcinoma lung cancer (ADLC) plasmas by lectin-capturing and targeted mass spectrometry.
    Ahn YH; Ji ES; Oh NR; Kim YS; Ko JH; Yoo JS
    J Proteomics; 2014 Jun; 106():221-9. PubMed ID: 24780727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer.
    Zhou M; Kong Y; Wang X; Li W; Chen S; Wang L; Wang C; Zhang Q
    Biomed Res Int; 2021; 2021():5561569. PubMed ID: 33728331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the Soluble and Extracellular Vesicle Protein Compartments of Plasma Using In-Depth Mass Spectrometry-Based Proteomics.
    Sharma N; Angori S; Sandberg A; Mermelekas G; Lehtiö J; Wiklander OPB; Görgens A; Andaloussi SE; Eriksson H; Pernemalm M
    J Proteome Res; 2024 Sep; 23(9):4114-4127. PubMed ID: 39141927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.
    Del Pilar Chantada-Vázquez M; López AC; Vence MG; Vázquez-Estévez S; Acea-Nebril B; Calatayud DG; Jardiel T; Bravo SB; Núñez C
    J Proteomics; 2020 Feb; 212():103581. PubMed ID: 31731051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry.
    Zeng X; Hood BL; Zhao T; Conrads TP; Sun M; Gopalakrishnan V; Grover H; Day RS; Weissfeld JL; Wilson DO; Siegfried JM; Bigbee WL
    J Thorac Oncol; 2011 Apr; 6(4):725-34. PubMed ID: 21304412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics analysis of human serum of patients with non-small-cell lung cancer reveals proteins as diagnostic biomarker candidates.
    Boccellino M; Pinto F; Ieluzzi V; Giovane A; Quagliuolo L; Fariello C; Coppola M; Carlucci A; Santini M; Ferati K; Bexheti-Ferati A; Giordano A; Di Domenico M
    J Cell Physiol; 2019 Dec; 234(12):23798-23806. PubMed ID: 31180588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Proteomic Technologies for Blood-Based Detection of Colorectal Cancer.
    Bhardwaj M; Terzer T; Schrotz-King P; Brenner H
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33530402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Method and platform standardization in MRM-based quantitative plasma proteomics.
    Percy AJ; Chambers AG; Yang J; Jackson AM; Domanski D; Burkhart J; Sickmann A; Borchers CH
    J Proteomics; 2013 Dec; 95():66-76. PubMed ID: 23933160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a Novel Plasma Protein Signature for Breast Cancer Diagnosis by Using Multiple Reaction Monitoring-based Mass Spectrometry.
    Lee HB; Kang UB; Moon HG; Lee J; Lee KM; Yi M; Park YS; Lee JW; Yu JH; Choi SH; Cho SH; Lee C; Han W; Noh DY
    Anticancer Res; 2015 Nov; 35(11):6271-9. PubMed ID: 26504062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isotope coded protein label quantification of serum proteins--comparison with the label-free LC-MS and validation using the MRM approach.
    Turtoi A; Mazzucchelli GD; De Pauw E
    Talanta; 2010 Feb; 80(4):1487-95. PubMed ID: 20082806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry.
    Zeng X; Hood BL; Sun M; Conrads TP; Day RS; Weissfeld JL; Siegfried JM; Bigbee WL
    J Proteome Res; 2010 Dec; 9(12):6440-9. PubMed ID: 20931982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Depth and Breadth of Plasma Protein Quantitation via Two-Dimensional Liquid Chromatography/Multiple Reaction Monitoring-Mass Spectrometry with Labeled Peptide Standards.
    Percy AJ; Yang J; Chambers AG; Borchers CH
    Methods Mol Biol; 2016; 1410():1-21. PubMed ID: 26867735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced sensitivity and multiplexing with 2D LC/MRM-MS and labeled standards for deeper and more comprehensive protein quantitation.
    Percy AJ; Simon R; Chambers AG; Borchers CH
    J Proteomics; 2014 Jun; 106():113-24. PubMed ID: 24769237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry.
    Quon BS; Dai DL; Hollander Z; Ng RT; Tebbutt SJ; Man SF; Wilcox PG; Sin DD
    Thorax; 2016 Mar; 71(3):216-22. PubMed ID: 25777587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
    Lee SM; Upadhyay S; Lewanski C; Falk S; Skailes G; Woll PJ; Hatton M; Lal R; Jones R; Toy E; Rudd R; Ngai Y; Edwards A; Hackshaw A
    Eur J Cancer; 2019 Oct; 120():86-96. PubMed ID: 31499384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS.
    Shin J; Song SY; Ahn HS; An BC; Choi YD; Yang EG; Na KJ; Lee ST; Park JI; Kim SY; Lee C; Lee SW
    PLoS One; 2017; 12(8):e0183896. PubMed ID: 28837649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.